What is a key hepatic safety consideration when using gepants?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Gepants can affect the liver, so hepatic safety is a key consideration. Early experience with the class showed that liver injury could occur, especially with higher exposure, so hepatic function must be taken into account when using these drugs. If a patient has hepatic impairment, drug exposure can change, potentially requiring dose adjustments or avoidance depending on the specific gepant. Because gepants are metabolized by CYP enzymes, particularly CYP3A4, strong inhibitors of this enzyme can raise gepant levels and increase the risk of liver-related adverse effects; therefore, use with strong CYP3A4 inhibitors should be avoided or carefully managed with dose adjustments as recommended. Monitoring liver function tests is important during therapy, especially in patients with existing liver disease or new symptoms suggestive of hepatic dysfunction. In short, hepatic impairment may necessitate dose adjustments, interactions with strong CYP3A4 inhibitors require caution or avoidance, and liver function monitoring should be part of ongoing safety assessment.